<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564651</url>
  </required_header>
  <id_info>
    <org_study_id>013</org_study_id>
    <nct_id>NCT04564651</nct_id>
  </id_info>
  <brief_title>Platelet Transfusion in Acute-on Chronic Liver Failure</brief_title>
  <official_title>Platelet Transfusion in Acute-on Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute on-chronic liver failure (ACLF) is a severe liver disease with a 28-day mortality rate&#xD;
      of up to 40%. When the patients get 3 or more organ failures, the 28-day mortality rate is up&#xD;
      to 82.6%. Though the ACLF patients have high short-term mortality, and the only effective&#xD;
      treatment method is liver transplantation. However, few patients can be treated due to the&#xD;
      scarcity of liver source, rapid disease progression and short transplantation window.&#xD;
&#xD;
      Our team evaluated the platelet function of 100 patients with ACLF by using the&#xD;
      thromboelastograghy (TEG 5000). It was found for the first time that the reactivity of&#xD;
      platelets of ACLF patients decreased, and the platelet inhibition rate (especially the ADP&#xD;
      pathway) was related to patients'short-term prognosis. When the ADP inhibition rate was 70%,&#xD;
      the patients'28-day mortality was up to 100%. However, the mechanism of low platelet response&#xD;
      to ADP in ACLF patients is still unclear. We found that the platelet function in patients&#xD;
      with ACLF 2-3 grade and inhibition rate beyond 70% was improved and the 28-day mortality&#xD;
      decreased after platelet transfusion. Whether platelet transfusion can prolong survival time&#xD;
      needs to be determined in a prospective controlled study. Therefore, this study is expected&#xD;
      to find a new therapeutic method to reduce the mortality of patients with ACLF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day transplant-free mortality</measure>
    <time_frame>28 days</time_frame>
    <description>whether participant died or not without liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-day transplant-free mortality</measure>
    <time_frame>90 days</time_frame>
    <description>mortality without transplant in 90 day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>platelet transfusion treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>platelet transfusion</intervention_name>
    <description>when the ADP inhibition &gt;70%, give one unit platelet tansfusion</description>
    <arm_group_label>platelet transfusion treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-60 years old;&#xD;
&#xD;
          -  Patients with compensated cirrhosis conformed to the (ACLF) diagnostic criteria of&#xD;
             chronic and acute liver failure defined by the European Association of Hepatology&#xD;
             (EASL-CLIF), and met the ACLF-2 and 3 grades.&#xD;
&#xD;
        ADP inhibition rate â‰¥ 70%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe platelet allergy in the past;&#xD;
&#xD;
          -  Coma caused by cerebral hemorrhage or primary diseases of the nervous system;&#xD;
&#xD;
          -  Those who have taken anti-platelet drugs or anticoagulants within four weeks;&#xD;
&#xD;
          -  Rupture and bleeding of EVB occurred within 1 week.&#xD;
&#xD;
          -  Those who received platelet transfusion within 1 week;&#xD;
&#xD;
          -  Patients with liver cancer or other malignant tumors;&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  Complicated with other serious chronic diseases;&#xD;
&#xD;
          -  Not signing the informed consent form;&#xD;
&#xD;
          -  Other researchers do not consider it appropriate to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Jinjun</last_name>
    <phone>+8618588531001</phone>
    <email>chjj@smu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Tingting</last_name>
    <phone>+8615521287260</phone>
    <email>tingtingqi@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Xia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Chen</last_name>
      <phone>+8615521287260</phone>
      <email>chjj@smu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tingting Qi</last_name>
      <phone>+8615521287260</phone>
      <email>tingtingqi@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Taihe Hospital affiliated to Hubei Medical College</name>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongji Meng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pujun Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Xinjiang</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobo Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meng Chao Hepatobiliary Hospital of Fujian Medical University</name>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuxiong Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiping Qian</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Jinjun Chen</investigator_full_name>
    <investigator_title>Associate Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

